ClinicalTrials.gg
CompletedNCT03338426FIESTAUpdated Nov 5, 2019

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

A Phase 3 interventional study of Fimasartan 120mg and Atorvastatin 40mg in Essential Hypertension, Dyslipidemia, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-05.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing fimasartan in Essential Hypertension — none open to participants now, none under way, none of them phase 3. fimasartan · Essential Hypertension.

Enrollment
10th of 21
133 · median 92
Started
2018
the only one that year
Phase 3
9 of 21
none open now
Registered
18th of 21
by date
Lead sponsor
20 of 21
Boryung Pharmaceutical Co., Ltd

Among the 21 studies testing fimasartan in Essential Hypertension, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 9 in phase 3, and was the 18th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 21 studies testing fimasartan in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

Where they have run

About fimasartan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing fimasartan in Essential Hypertension as a file.
02

Study summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.

03

Conditions studied

  • Essential Hypertension, Dyslipidemia
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily provided a written consent to participate in this clinical study
  2. Male or female adults aged 19-70 years
  3. Patients must have been confirmed essential hypertension and dyslipidemia at Screening visit (V1)
  4. Uncontrolled blood pressure (140 mmHg ≤ mean SiSBP \< 180 mmHg) at the pre- baseline visit (V2) after
  5. Able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion

Exclusion criteria

Exclusion Criteria:

  1. Severe hypertension with mean Sitting systolic blood pressure(SiSBP)≥180 mmHg or Sitting diastolic blood pressure(SiDBP) ≥110 mmHg at the screening visit (V1) and the pre-baseline visit (V2), or orthostatic hypotension accompanied by symptoms
  2. Difference of Sitting systolic blood pressure(SiSBP) ≥ 20 mmHg and Sitting diastolic blood pressure(SiDBP) ≥ 10 mmHg between Lt and Rt arms for 3 consecutive times at the screening visit (V1)
  3. Secondary hypertension patients: Secondary hypertension is not limited to the following diseases; (e.g., renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney disease)
  4. Uncontrolled diabetes mellitus (currently on insulin, or >9% at the pre-baseline visit (V2)), or uncontrolled hypothyroidism (TSH ≥1.5 times the upper limit at the pre-baseline visit (V2))
  5. Heart disease (heart failure of (NYHA) class 3 and 4), or ischemic heart disease (angina pectoris, myocardial infarction), peripheral vascular diseasenewly diagnosed within 6 months prior to the screening visit (V1), percutaneous transluminal coronary angioplasty, or coronary artery bypass graft, etc.
  6. ventricular tachycardia, atrial fibrillation, atrial flutter; or other arrhythmia conditions that are determined to be clinically significant by the investigator
  7. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, or hemodynamically significant aortic valve stenosis or mitral valve stenosis
  8. Cerebrovascular disorder (stroke, cerebral infarction, transient cerebral ischemic attack, cerebral hemorrhage, etc. within 6 months prior to the screening visit (V1)
  9. Pregnant or lactating women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Experimental

    Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg

    Drug: Fimasartan 120mg · Drug: Atorvastatin 40mg

  • Active comparator
    Active Comparator 1

    Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg

    Drug: Fimasartan 120mg · Drug: Placebo for Atorvastatin 40mg

  • Active comparator
    Active Comparator 2

    Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg

    Drug: Atorvastatin 40mg · Drug: Placebo for Fimasartan 120mg

Interventions

  • Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

  • Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

  • DrugPlacebo for Fimasartan 120mg

    Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

  • DrugPlacebo for Atorvastatin 40mg

    Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

06

What researchers measure

Primary outcomes

  1. SiSBP

    The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 2(Atorvastatin 40mg)

    Time frame: 8weeks from Baseline Visit

  2. LDL-C

    The change in LDL-C from baseline in the test group at Week 8 compared to the active comparator group 1(fimasartan 120 mg)

    Time frame: 8weeks from Baseline Visit

Secondary outcomes

  1. SiSBP

    The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 1(Fimasartan 120mg)

    Time frame: 8weeks from Baseline Visit

  2. LDL-C

    The change in LDL-C from baseline in the test group(Fimasartan 120mg/Atorvastatin 40mg) at Week 8 compared to the Active Comparator group 2(Atorvastatin 40mg)

    Time frame: 8weeks from Baseline Visit

07

Study locations

1 site
  • Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2019, 15 months.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 15 months is close to that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 9, 2017
StartActual
Jan 15, 2018
Primary completionActual
Apr 22, 2019
CompletionActual
Apr 22, 2019
Last update
Nov 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03338426
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Jan 15, 2018
Primary completion
Apr 22, 2019
Completion
Apr 22, 2019
Last update
Nov 5, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fimasartan · Atorvastatin

Start the discussion